As parties gear up for the first bellwether trials to start soon in state court over the blood thinner Xarelto, disputes have arisen over whether punitive damages should be allowed into the cases, and what experts should be allowed to testify.
On Sept. 8, pharmaceutical giant Bayer asked the Philadelphia Court of Common Pleas to dismiss punitive damages from two cases—one of which is set to go before a jury in November. The same day liaison counsel for the plaintiffs filed two motions seeking to bar defense experts from testifying that attorney advertising can lead to an increase in bleeding incidents, or that bleeding incidents can be beneficial, as they can lead to early diagnoses of conditions like cancer that are typically not easily detectable.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
